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Methods. Forty-five genetically characterised DMD boys (mean age 8.7±2.76 years)
were compared with 22 controls (mean age 9±2.96 years). All patients were without clin-
ical symptoms from the cardiovascular system and had normal conventional echocardio-
grams. We used the HDI 5000 (Philips Medical Systems) to acquire from the parasternal
long axis the colour M-mode tissue Doppler (TDI) of the posterior wall of the LV. Images
were digitally stored for offline analysis with dedicated software HDI-lab (Philips Medical
Systems). We calculated the SR using the formula SR=Ua-Ub/d where U the velocities of
the endocardium a and epicardium b, and d their distance at each time point. We defined
TR as the time from the R-wave of the ECG trace to the transition point of SR from posi-
tive to negative values. The TR values were corrected for the heart rate using the Bazett’s
formula and expressed in msec.
Results. There were no significant differences for the 2D and Doppler parameters from
the conventional echocardiographic studies of the two groups. SR in the DMD boys was
found to be significantly lower at systole (1,78±0,75s-1 vs. 2,82±0,5s-1, p<0,000) and
early diastole (-5,17±1,98s-1vs.-9,02±1,25s-1, p<0,000) but not at late diastole (-
1,52±0,84s-1vs.-1.6±0,46s-1, p<0,568). TRcorrected for the heart rate was found to be
higher in patients with DMD (384,47±40,12msec vs. 364,54±23,43msec), P<0.003.
Conclusion. SR measurements and SR TR were significantly different in asymptomatic
boys with DMD showing systolic and diastolic dysfunction at early stages and when con-
ventional echocardiographic studies are still normal.
1013-114 Improvement of Endothelial Function in Patients With 
Myocardial Inflammation by Angiotensin-Converting 
Enzyme Inhibition With Quinapril: A Randomized 
Double-Blind, Placebo Controlled Study
Katja B. Vallbracht, Uwe Kuehl, Peter L. Schwimmbeck, Bettina Seeberg, Heinz-Peter 
Schultheiss, Charite Medical University, Campus Benjamin Franklin Hospital, Berlin, 
Germany
Background
In patients with inflammatory cardiomyopathy (InfCM), immunohistological evaluation of
myocardial biopsies demonstrates an inflammatory response in myocardium and blood
vessels, which is associated with endothelial dysfunction. The aim of this study is to
investigate an improvement of inflammatory endothelial dysfunction by ACE-inhibition.
Methods
In 46 patients with suspected InfCM myocardial biopsies were obtained. They were ran-
domly assigned to treatment with quinapril (20-40 mg) or placebo for 6 months, double
blind. Endothelial function (ENF) was examined by high resolution ultrasound, measuring
flow mediated vasodilation (FMD) of the radial artery in response to reactive hyperemia
and endothelium independent vasoreactivity to glyceroltrinitrate, at the beginning of the
study and after 6 months.
Results
In 40 patients, myocardial inflammation (InfCM) was confirmed by immunohistology in
myocardial biopsies, 6 had normal myocardial biopsies. Mean age of the 18 male and 22
female patients was 43±12 years. In the quinapril-group (n=21), FMD increased signifi-
cantly from 3.34±2.78% at inclusion to 7.56±3.97% after 6 months (p<0.001). In the pla-
cebo-group (n=19), FMD decreased from 4.30±2.93% at inclusion to 3.53±2.41% after 6
months (p=0.287). GTN-MD was not changed significantly (25.75±9.1%). Mean EF
increased from 61.3±13.6% at inclusion to 64.3±9.4 after 6 months (p=0.040) in the
quinapril-group and from 56.2±18.6% to 59.7±15.6% (p=0.247) in the placebo-group. 20
patients had a second myocardial biopsy after 6 months, 11 in the placebo-group and 9
in the quinapril-group. All second biopsies showed persistent myocardial inflammation.
Conclusions
Endothelial dysfunction in patients with myocardial inflammation can be improved with
the ACE-inhibitor quinapril, as compared to placebo. This improvement is not due to elim-
ination of the myocardial inflammatory process or improvement of LV function. We con-
clude that ACE-inhibition directly improves endothelial dysfunction in patients with
myocardial inflammation.
1013-115 Familial Predisposition for Inflammatory 
Cardiomyopathy
Bernhard Maisch, Irene Portig, Andreas Wilke, Anette Richter, Volker Ruppert, Arsen D. 
Ristic, Guenther Hufnagel, Sabine Pankuweit, Philipps-University, Marburg, Germany
Introduction: Familial dilated cardiomyopathy (DCM) has been reported in the past. Fam-
ily screening identified DCM as an inherited disorder in up to 30%. Familial DCM (fDCM)
is phenotypically heterogeneous. Genetic and environmental factors may play pathoge-
netic roles. Since DCM results in some patients from chronic inflammation, we analysed
our Marburg DCM registry for familial inflammatory cardiomyopathy.
Methods: 208 consecutive index patients with inflammatory DCM were included in our
study (criteria: enlarged left ventricle (Henry Index ³ 117%), reduced ejection fraction
(<50%), histological evidence of an inflammatory infiltrate (³14 leucocytes / mm2 prefera-
bly activated T cells) in endomyocardial biopsies). Using a questionnaire, index patients
were selected for family studies comprising clinical examination, electrocardiography,
echocardiography, and blood sampling. Familial inflammatory DCM was diagnosed,
when at least one first degree relative met the criteria for DCM, died suddenly before the
age of 35, had pericardial effusion or both cardiac arrythmia and left ventricular dilatation.
Results: 8 index patients (4%) were identified. Mode of inheritence varied: autosomal
dominant in 4 families, autosomal or X-chromosomal dominant in 1, maternally inherited
in 1, autosomal dominant with skeletal muscle disease in 1, and with conduction defect in
1 family. Viral genome was undetectable in endomyocardial biopsies of all index patients.
Conclusion: Inflammatory DCM should be considered an independent disease entity, the
etiology of which is yet to be established. Genetic predisposition to viral/autoimmune
mechansims may be of importance. In our patients predisposition to autoimmune myo-
carditis was found exclusively.
1013-116 Impact of Left Ventricular Remodeling Upon Ventricular 
Ectopic Activity in Patients With Preserved Systolic 
Function
Jason A. Mitchell, Richard V. Milani, Carl J. Lavie, Frank H. Messerli, Ochsner Clinic 
Foundation, New Orleans, LA
Background: LVH by ECG criteria is associated with ectopic density, increased rates of
complex ventricular ectopy, and ultimately sudden cardiac death (SCD). Although we and
others have demonstrated that early LV concentric remodeling (CR) is associated with
increased morbid CV events and mortality, the association between CR and complex
ventricular ectopic activity (VEA) has not been studied.
We sought to evaluate the effect of LV structure on VEA and mortality from a combined
echocardiographic and holter database of 4,601 patients with preserved LV function (EF
> 50%).
Using published criteria utilizing relative wall thickness (RWT), and LV mass index
(LVMI), we classified patients as normal (normal RWT and LVMI), CR (increased RWT,
normal LVMI), concentric hypertrophy (CH) (increased RWT and increased LVMI) and
eccentric hypertrophy (EH) (normal RWT, increased LVMI). (*p<0.05) 
Patients with hypertrophy had a mortality rate 3 times that of normals. Although patients
with CR had the lowest rate of VEA, their mortality was double that of normals.
Conclusion: LV hypertrophy, particularly EH, is associated with increased VEA and mor-
tality among patients with normal EF, supporting increased SCD in this population. CR
revealed the lowest VEA, but is associated with more than twice the mortality of patients
with normal LV geometry suggesting a non-electrical cause of death.
1013-117 HIV Cardiomyopathy Is Rare in the Era of Highly Active 
Antiretroviral Therapy
Neil W. Siecke, Keyvan Jahanbakhsh, Thomas Waltman, Ori Ben-Yehuda, University of 
California, San Diego, San Diego, CA
Background: HIV Cardiomyopathy remains poorly understood, with limited data on its
incidence in the era of highly active anti-retroviral therapy.
Methods: Retrospective chart review of all HIV+ patients seen at the UCSD HIV Clinic
who had an echocardiogram (TTE) during 2001-2003. Control population of all subjects
with TTEs during the same period.
Results: 244/2849 (8.5%) HIV patients had a TTE and 19 subjects had moderate to
severe LV dysfunction (8% of HIV + subjects with a TTE; 0.7% of HIV + population).
Compared with 12,283 control patients, HIV+ subjects were younger (46 vs. 60 p <
0.001) and had a slightly lower average ejection fraction (EF) (58.1% vs 59.9%, p = 0.02)
but a trend towards fewer subjects with EF < 45% (9% vs 14%, p=0.06) . There was no
correlation between the EF and the most recent or lowest CD4 count or viral load. There
was no association between LV dysfunction and CMV infection, testosterone deficiency,
malnutrition, or HIV encephalopathy. All 19 HIV+ patients with moderate or severe LV
dysfunction had a plausible reason for depressed LV function; CAD in all 10 patients over
age 50; alcohol abuse (3), adriamycin use (1), polysubstance abuse (3), and active sep-
sis (2) in those under 50.
Conclusions: The incidence of LV dysfunction was similar in HIV + and non-infected
persons referred for TTE. HIV+ patients with LV dysfunction had traditional risk factors for
LV dysfunction; there was no correlation with the severity of HIV infection, or conditions
associated with HIV infection, and LV dysfunction. 
LV Geometry Number Mean PVC’s/hour Mean VT runs/24h Mortality(%)
Normal 2189 35.4 0.46 1.7
CR 1333 26.6* 0.07* 4.2*
CH 309 38.4* 0.24* 5.7*
EH 261 47.5* 3.5* 5.2*
HIV Status vs. EF less than 45%
EF Less than 45% Total
EF > 45% EF < 45%
HIV Status HIV Positive 203
(90.6%)
21
(9.4%)
224
(100%)
Control 9464
(86.3%)
1507
(13.7%)
10971
(100%)
Total 9667
(86.3%)
1528
(13.7%)
11195
(100%)
p=0.06 by Chi Square
